Snowden Capital Advisors LLC Mirati Therapeutics, Inc. Transaction History

Snowden Capital Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $113,285 - $184,801	4,075 Added 55.59%	11,405 $496,000
Q2 2023 Aug 14, 2023	SELL	$36.13 - $49.49 $578 - $791	-16 Reduced 0.22%	7,330 $264,000
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $8,915 - $13,239	244 Added 3.44%	7,346 $273,000
Q4 2022 Feb 13, 2023	BUY	$41.27 - $98.62 $75,936 - $181,460	1,840 Added 34.97%	7,102 $321,000
Q3 2022 Nov 09, 2022	BUY	$59.5 - $86.7 $107,873 - $157,187	1,813 Added 52.57%	5,262 $367,000
Q2 2022 Aug 12, 2022	BUY	$39.16 - $88.71 $135,062 - $305,960	3,449 New	3,449 $231,000
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $41,700 - $83,033	-550 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $72,605 - $104,659	550 New	550 $80,000
Q1 2020 Jan 08, 2024	SELL	$69.78 - $116.21 $4.19 Million - $6.97 Million	-60,000 Closed	0 $0
Q4 2019 Jan 08, 2024	SELL	$70.76 - $128.86 $7.5 Million - $13.7 Million	-106,000 Reduced 63.86%	60,000 $77.3 Million
Q3 2019 Jan 08, 2024	BUY	$77.91 - $109.6 $12 Million - $16.9 Million	154,595 Added 1355.5%	166,000 $129 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Snowden Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Snowden Capital Advisors LLC with notifications on news.